PDAPS | Prescription Drug Abuse Policy System


Papers in Peer-Reviewed Publications Citing PDAPS
  1. 1

    Adams, N. Gundlach, E. & Cheng C. (2020).

    An Analysis of State-Level Policies and Opioid Overdose Deaths.

    Western Journal of Nursing Research, https://journals.sagepub.com/doi/full/10.1177/0193945919897538

  2. 2

    Burris S (2020).

    Research on the Effects of Legal Health Interventions to Prevent Overdose: Too Often Too Little and Too Late

    American Journal of Public Health, https://doi.org/10.2105/AJPH.2020.305678

  3. 3

    Davidson, P., Chakrabarti, P., & Marquesen, M. (2020).

    Impacts of mandated data collection on syringe distribution programs in the United States

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/abs/pii/S0955395920300669

  4. 4

    Ghimire, K. & Maclean, J. (2020).

    Medical marijuana and workers' compensation claiming

    Health Economics, https://onlinelibrary.wiley.com/doi/abs/10.1002/hec.3992

  5. 5

    Jacksona, J. R., Harle, C., Silverman, R., Simon, K., & Menachemib, N. (2020).

    Characterizing variability in state-level regulations governing opioid treatment programs

    Journal of Substance Abuse Treatment, https://www.sciencedirect.com/science/article/abs/pii/S0740547219307081

  6. 6

    Kim, C., Lefkowitsb, C., Holschneiderc, C., Bixeld, K., & Pothurie, B (2020).

    Managing opioid use in the acute surgical setting: A society of gynecologic oncology clinical practice statement

    Gynecologic Oncology, https://www.gynecologiconcology-online.net/article/S0090-8258(20)30068-8/fulltext

  7. 7

    Mallinson, D., & Hannah, A. (2020).

    Policy and Political Learning: The Development of Medical Marijuana Policies in the States

    The Journal of Federalism, https://academic.oup.com/publius/article-abstract/doi/10.1093/publius/pjaa006/5819235

  8. 8

    Nguyen, J. et al. (2020).

    Availability of Naloxone at Rural Georgia Pharmacies, 2019

    JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760889

  9. 9

    Schneider K. et al. (2020).

    Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone.

    International Journal of Drug Policy, https://www.sciencedirect.com/science/article/pii/S095539591930355X

  10. 10

    Shakya, S. (2020).

    County Level Assessment of Prescription Drug Monitoring Program and Opioid Prescription Rate

    John Chambers College of Business and Economics & Regional Research Institute (RRI), West Virginia University https://shishirshakya.github.io/files/Papers/County_Level_Assessment_of_Prescription_Drug_Monitoring_Program_and_Opioid_Prescription_Rate.pdf

  11. 11

    Sohn, M. et al. (2020).

    Association between state Medicaid expansion status and naloxone prescription dispensing

    Health Services Research, https://onlinelibrary.wiley.com/doi/full/10.1111/1475-6773.13266

  12. 12

    Tan de Bibiana, J., Miller, C., Pope, L., Stellin, S., Parsons, J., & Cloud, D. (2020).

    Changing Course in the Overdose Crisis: Moving from Punishment to Harm Reduction and Health

    Vera, Institute of Justice, https://www.vera.org/downloads/publications/changing-course-in-the-overdose-crisis.pdf

  13. 2019
  14. 1

    Allen, S.T., Hamilton White, R., O’Rourke, A., Grieb, S.M., Kilkenny, M.E., Sherman, S.G. (2019).

    Take-home naloxone possession among people who inject drugs in rural West Virginia.

    Drug and Alcohol Dependence, Vol. 204, November 1, 2019. https://doi.org/10.1016/j.drugalcdep.2019.107581

  15. 2

    Bach, P., Hartung, D. (2019).

    Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. 14:30.

    Addiction Science & Clinical Practice. 14:30. https://doi.org/10.1186/s13722-019-0158-0

  16. 3

    Cariveau, D., Fay, A.E., Baker, D., Fagan, E.B., Gilmore Wilson, C. (2019).

    Evaluation of a pharmacist-led naloxone coprescribing program in primary care.

    Journal of the American Pharmacists Association, Volume 0, Issue 0. https://doi.org/10.1016/j.japh.2019.07.012

  17. 4

    Chan, N.W., Burkhardt, J., Flyr, M. (2019).

    The Effects of Recreational Marijuana Legislation and Dispensing on Opioid Mortality.

    Econ Inq. doi:10.1111/ecin.12819.

  18. 5

    Chisholm-Burns, M.A., Spivey, C.A., Sherwin, E., Wheeler, J., Hohmeier, K. (2019).

    The opioid crisis: Origins, trends, policies, and the roles of pharmacists.

    American Journal of Health-System Pharmacy, 76(7), 424-435, doi: https://doi.org/10.1093/ajhp/zxy089

  19. 6

    Desai, R.J., Jin, Y., Franklin, P.D., Lee, Y.C., Bateman, B.T., Lii, J., Solomon, D.H., Katz, J.N., Kim, S.C. (2019).

    Association of Geography and Access to Health Care Providers with Long-Term Prescription Opioid Use in Medicare Patients with Severe Osteoarthritis: A Cohort Study.

    Arthritis & Rheumatology, 71:5, 712-721, May 2019. https://doi.org/10.1002/art.40834

  20. 7

    Diang L, Shi Y. (2019).

    The association between pain clinic laws and prescription opioid exposures: New evidence from multi-state comparisons.

    Drug and Alcohol Dependence, https://www.sciencedirect.com/science/article/pii/S0376871619305319

  21. 8

    Donohue, J.M., Kennedy, J.N., Seymour, C.W., Girard, T.D., Lo-Ciganic, W.H., Kim, C.H., Marroquin, O.C., Moyo, P., Chang, C.C.H., Angus, D.C. (2019).

    Patterns of opioid administration among opioid-naive inpatients and associations with postdischarge opioid use.

    Ann. Intern. Med. Published online June 18, 2019. doi:10.7326/M18-2864

  22. 9

    Fletcher, J., Molloy, M., Hart, A., Voskanyan, A., Sarin, R., & Ciottone, G. (2019).

    Evolution of United States Legislation to Facilitate Bystander Response to Opioid Overdose.

    Prehospital and Disaster Medicine, 34(S1), S130-S130. doi:10.1017/S1049023X19002826

  23. 10

    Frank, R.G., Fry, C.E. (2019).

    The Impact of Expanded Medicaid Eligibility on Access to Naloxone.

    Addiction. https://doi.org/10.1111/add.14634

  24. 11

    Fudin, J., Persico, A. L., Bettinger, J. J., & Wegrzyn, E. L. (2019).

    The state of naloxone: Access amid a public health crisis.

    Medicine Access @ Point of Care. https://doi.org/10.1177/2399202619847639

  25. 12

    Haas, E. (2019).

    Health and Social Services F-4 The Opioid Crisis

    Kansas Legislator Briefing Book 2019, http://www.kslegresearch.org/KLRD-web/Publications/BriefingBook/2019Briefs/F-4-TheOpioidCrisis.pdf

  26. 13

    Haffajee, R., French, C.A. (2019).

    Provider Perceptions of System-Level Opioid Prescribing in Addiction Treatment Policies.

    Current Opinion in Psychology 2019. doi: https://doi.org/10.016/j.copsyc.2019.01.018

  27. 14

    Hohmann, L. (2019).

    An untapped potential in addressing the opioid epidemic.

    Journal of the American Pharmacists Association 59, 625-627. https://www.japha.org/article/S1544-3191(19)30358-9/pdf

  28. 15

    Kravitz-Wirtz N. et al. (2019).

    Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.

    JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2758476

  29. 16

    Lowenstein, M., Hossain, E., Yang, W., Grande, D., Perrone, J., Neuman, M.D., Ashburn, M., Delgado, M.K. (2019).

    Impact of a State Opioid Prescribing Limit and Electronic Medical Record Alert on Opioid Prescriptions: a Difference-in-Differences Analysis.

    J. Gen. Intern. Med. https://doi.org/10.1007/s11606-019-05302-1

  30. 17

    Martins, S.S., Ponicki, W., Smith, N., Rivera-Aguirre, A., Davis, C.D., Fink, D.S., Castillo-Carniglia, A., Henry, S.G., Marshall, B.D.L., Gruenewald, P., Cerda, M. (2019).

    Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.

    Int’l J. of Drug Policy, 74: 174-180. https://doi.org/10.1016/j.drugpo.2019.10.001

  31. 18

    Moyo, P., Simoni-Wastila, L., Griffin, B.A., Harrington, D., Alexander, G.C., Palumbo, F., & Onukwugha, E. (2019).

    Prescription drug monitoring programs: Assessing the association between “best practices” and opioid use in Medicare.

    Health Serv. Res. 2019; 00. 1-10. https://doi.org/10.1111/1475-6773.13197

  32. 19

    Ruhm, C. (2019).

    Drivers of the fatal drug epidemic.

    Journal of Health Economics, 64 (2019) 25-42. doi: https://doi.org/10.1016/j.healeco.2019.01.001

  33. 20

    Smart R., Kase C., Taylor E., Stein B. (2019).

    Strengths and Weaknesses of Existing Data Sources to Support Research to Address the Opioids Crisis.

    Preventive Medicine Reports, https://doi.org/10.1016/j.pmedr.2019.101015

  34. 21

    Smith, J.O., Malinowski, S.S., Ballou, J.M. (2019).

    Public perceptions of naloxone use in the outpatient setting.

    Mental Health Clinician: July 2019, Vol. 9, No. 4, pp. 275-279. https://doi.org/10.9740/mhc.2019.07.275

  35. 22

    Strang, J., McDonald, R., Campbell, G., Degenhardt, L., Nielsen, S., Ritter, A., & Dale, A. (2019).

    Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.

    Drugs, 1-24. https://doi.org/10.1007/s40265-019-01154

  36. 23

    Strickler, G.K., Zhang, K., Halpin, J.F., Bohnert, A.S.B., Baldwin, G.T., Kreiner, P.W. (2019).

    Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.

    Drug and Alcohol Dependence, 199, 1-9. https://doi.org/10.1016/j.drugalcdep.2019.02.010

  37. 24

    Whitmore, C.C., White, M.N., Buntin, M.B., Fry, C.E., Calamari, K., Patrick, S.W. (2019).

    State laws and policies to reduce opioid-related harm: A qualitative assessment of PDMPs and naloxone programs in ten U.S. States.

    Preventative Medicine Reports, 13, 249-255, March 2019. https://doi.org/10.1016/j.pmedr.2018.12.014

  38. 25

    Yarbrough, C.R., Abraham, A.J., Bagwell Adams, G. (2019).

    Relationship of county opioid epidemic severity to changes in access to substance use disorder treatment, 2009-2017.

    Psychiatric Services, Psychiatry Online. https://doi.org/10.1176/appi.ps.201900150

  39. 2018
  40. 1

    Alexandra, S., Fahad, K., Alina, B., Germaine, C., Christopher, G., & V., D. L. (2018).

    New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program.

    Cannabis and Cannabinoid Research, 3(1), 74-84. doi: 10.1089/can.2017.0046

  41. 2

    Bennett, A. S., Bell, A., Doe-Simkins, M., Elliott, L., Pouget, E., & Davis, C. (2018).

    From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA.

    Journal of Psychoactive Drugs, 1-7. doi: 10.1080/02791072.2018.1430409

  42. 3

    Buchmueller, T. C., & Carey, C. (2018).

    The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare.

    American Economic Journal: Economic Policy, 10(1), 77-112. doi: doi: 10.1257/pol.20160094

  43. 4

    Freeman, P. R., Hankosky, E. R., Lofwall, M. R., & Talbert, J. C. (2018).

    The changing landscape of naloxone availability in the United States, 2011 – 2017.

    Drug and Alcohol Dependence, 191, 361-364. doi: https://doi.org/10.1016/j.drugalcdep.2018.07.017

  44. 5

    Gertner, A. K., Domino, M. E., & Davis, C. S. (2018).

    Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.

    Drug Alcohol Depend, 190, 37-41. doi: 10.1016/j.drugalcdep.2018.05.014

  45. 6

    Goldberg, S. A., Dworkis, D. A., Liao, V. T., Eyre, A. J., Albert, J., Fawcett, M. M., . . . Weiner, S. G. (2018).

    Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose.

    Prehospital Emergency Care, 1-7. doi: 10.1080/10903127.2018.1461284

  46. 7

    Huang, L. C. (2018).

    Opioid Overdoses: A Webliography.

    Journal of Consumer Health on the Internet, 22(1), 42-52. doi: 10.1080/15398285.2018.1415597

  47. 8

    McClellan, C., Lambdin, B. H., Ali, M. M., Mutter, R., Davis, C. S., Wheeler, E., . . . Kral, A. H. (2018).

    Opioid-overdose laws association with opioid use and overdose mortality.

    Addictive Behaviors, 86, 90-95. doi: https://doi.org/10.1016/j.addbeh.2018.03.014

  48. 9

    Pauly, N. J., Slavova, S., Delcher, C., Freeman, P. R., & Talbert, J. (2018).

    Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.

    Drug and Alcohol Dependence, 184, 26-32. doi: https://doi.org/10.1016/j.drugalcdep.2017.12.002

  49. 10

    Xu, J., Davis, C. S., Cruz, M., & Lurie, P. (2018).

    State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.

    Drug & Alcohol Dependence, 189, 37-41. doi: 10.1016/j.drugalcdep.2018.04.020

  50. 11

    Lambdin, B. H., Zibbell, J., Wheeler, E., & Kral, A. H. (2018).

    Identifying gaps in the implementation of naloxone programs for laypersons in the United States.

    International Journal of Drug Policy, 52, 52-55. doi: https://doi.org/10.1016/j.drugpo.2017.11.017

  51. 12

    W. Ling, V. Nadipelli, N. Ronquest, V. Albright, A. Aldridge, S. Learned, V. Mehra, C. Heidbreder,

    Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics. Concli (2018),


  52. 2017
  53. 1

    Burris, S. (2017).

    Theory and methods in comparative drug and alcohol policy research: Response to a review of the literature.

    International Journal of Drug Policy, 41, 126-131. doi: http://dx.doi.org/10.1016/j.drugpo.2016.11.011

  54. 2

    Compton, W. M., Volkow, N. D., & Lopez, M. F. (2017).

    Medical marijuana laws and cannabis use: Intersections of health and policy.

    JAMA Psychiatry, 74(6), 559-560. doi: 10.1001/jamapsychiatry.2017.0723

  55. 3

    Cushman, P. A., Liebschutz, J. M., Hodgkin, J. G., Shanahan, C. W., White, J. L., Hardesty, I., & Alford, D. P. (2017).

    What do providers want to know about opioid prescribing? A qualitative analysis of their questions.

    Substance Abuse, 38(2), 222-229. doi: 10.1080/08897077.2017.1296525

  56. 4

    Davis, C., & Carr, D. (2017).

    State legal innovations to encourage naloxone dispensing.

    Journal of the American Pharmacists Association, 57(2, Supplement), S180-S184. doi: https://doi.org/10.1016/j.japh.2016.11.007

  57. 5

    Klieger, S. B., Gutman, A., Allen, L., Pacula, R. L., Ibrahim, J. K., & Burris, S. (2017).

    Mapping medical marijuana: State laws regulating patients, product safety, supply chains and dispensaries, 2017.

    Addiction, n/a-n/a. doi: 10.1111/add.13910

  58. 6

    Lapham, G. T., Lee, A. K., Caldeiro, R. M., McCarty, D., Browne, K. C., Walker, D. D., . . . Bradley, K. A. (2017).

    Frequency of Cannabis Use Among Primary Care Patients in Washington State.

    The Journal of the American Board of Family Medicine, 30(6), 795-805. doi: 10.3122/jabfm.2017.06.170062

  59. 7

    Pardo, B. (2017).

    Do more robust prescription drug monitoring programs reduce prescription opioid overdose?

    Addiction, 112(10), 1773-1783. doi: 10.1111/add.13741

  60. 8

    Volkow, N. D., Compton, W. M., & Wargo, E. M. (2017).

    The risks of marijuana use during pregnancy.

    JAMA, 317(2), 129-130. doi: 10.1001/jama.2016.18612

  61. 2016
  62. 1

    Burris, S., Hitchcock, L., Ibrahim, J. K., Penn, M., & Ramanathan, T. (2016).

    Policy Surveillance: a Vital Public Health Practice Comes of Age.

    Journal of Health Politics, Policy & Law, 41(6), 1151-1167. doi: 10.1215/03616878-3665931

  63. 2

    Davis, C. S., Burris, S., Beletsky, L., & Binswanger, I. (2016).

    Co-prescribing naloxone does not increase liability risk.

    Substance Abuse, 37(4), 498-500. doi: 10.1080/08897077.2016.1238431

  64. 3

    Kitch, B. B., & Portela, R. C. (2016).

    Effective Use of Naloxone by Law Enforcement in Response to Multiple Opioid Overdoses.

    Prehospital Emergency Care, 20(2), 226-229. doi: 10.3109/10903127.2015.1076097

  65. 4

    Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016).

    Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.

    Health Affairs, 35, 1045-1051. doi: 10.1377/hlthaff.2015.1496

  66. 2015
  67. 1

    Green, T. C., Bowman, S., Davis, C., Los, C., McHugh, K., & Friedmann, P. D. (2015).

    Discrepancies in Addressing Overdose Prevention through Prescription Monitoring Programs.

    Drug & Alcohol Dependence. doi: 10.1016/j.drugalcdep.2015.05.009

  68. 2

    Rutkow, L., Chang, H., Daubresse, M., Webster, D. W., Stuart, E. A., & Alexander, G. (2015).

    Effect of Florida’s prescription drug monitoring program and pill mill laws on opioid prescribing and use.

    JAMA Internal Medicine, 175(10), 1642-1649. doi: 10.1001/jamainternmed.2015.3931

  69. 3

    Rutkow, L., Turner, L., Lucas, E., Hwang, C., & Alexander, G. C. (2015).

    Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access.

    Health Affairs, 34(3), 484-492. doi: 10.1377/hlthaff.2014.1085

Law Review Articles Citing PDAPS
  1. 1

    Lawrence, M.J.B. (2019). Deputizing Family: Loved Ones as a Regulatory Tool in the "Drug War" and Beyond. 11 Ne. U. L. Rev. 195.

  2. 2

    Mahoney, M. (2018). The Global Opioid Crisis: Effective Laws to Fight Rising Overdose Fatalities Through Access to Naloxone. 35 Ariz. J. Int’l & Comp. L. 531.

  3. 3

    Seligman, J. (2018). Confronting a Crisis: An Appraisal of Legislation in Louisiana Combating the Opioid Epidemic. 93 Tul. L. Rev. 147.

  4. 4

    Millikan, J. (2019). Last Line of Defense: How Indiana Can Encourage Naloxone Availability During Its Opioid Crisis. 52 Indiana L. Rev. 329.

Other Literature Citing PDAPS
  1. 1

    2019 Indiana Professional Licensure Program: Targeted Series of CME for Controlled Substances Registration Renewal (2019).

    InforMed Continuing Medical Education. https://in.cme.edu/CourseMaterials/2019%20Indiana%20Professional%20Licensure%20Program~dmltbrvhulmg4llqvrwzjkor3-1-2019%204-42-59%20PM.pdf

  2. 2

    Ackerman, E., Frazier, A., Jackson, S., Raczkowski, E. (2019). An Overview of Michigan’s Effort in Combating the Opioid Epidemic. Issue Paper: Papers Examining Critical Issues Facing the Michigan Legislature.

    Senate Fiscal Agency. April 2019.

  3. 3

    Alpert AE et al. (2019). Origins of the Opioid Crisis and Its Enduring Impacts.

    NBER Working Paper, https://www.nber.org/papers/w26500

  4. 4

    Bivens, K.M. (2019). Reducing harm by designing discourse and digital tools for opioid users’ contexts: the Chicago Recovery Alliance’s community-based context of use and PwrdBy’s technology-based context of use.

    Newsletter: Communication Design Quarterly Review. 7:2. pp. 17-27. July 2019. doi: 10.1145/3358931.3358935.

  5. 5

    Brooks, K., Davis, T., Nguyen, K., Nguyen, N-D., Rahman, T., Villa, L. (2019). Evaluating Naloxone Access and Prescribing Requirements in the Opioid Epidemic across the United States.

    Poster: Southwestern Oklahoma State University, College of Pharmacy. March 2019. https://dc.swosu.edu/cgi/viewcontent.cgi?article=1031&context=cop_pp_articles

  6. 6

    Clemans-Cope, L., Allen, E.H., Basurto, L., Lawrence, D., Kenney, G.M. (2019). Research Report: Leveraging Medicaid to Address Opioid and Substance Use Disorders in Maine: Ten State Policy Options from an Expedited Review. Urban Institute.


  7. 7

    Crum J. (2019). The mediating impact of punitive heroin laws on Naloxone access laws and opioid overdose fatalities.

    The American Society of Criminology Conference, https://convention2.allacademic.com/one/asc/asc19/index.php?cmd=Online+Program+View+Paper&selected_paper_id=1546300&PHPSESSID=ckbgh3kojq9pga3494ke7sp757

  8. 8

    Erfanian, Elham Three Essays on Utilizing Spatial Econometrics in Natural Resource Economics related to Water, Health, and Energy. (2019)

    Graduate Theses, Dissertations, and Problem Reports. 4053. https://researchrepository.wvu.edu/etd/4053

  9. 9

    Guy, G.P. Jr., Haegerich, T.M., Evans, M.E., Losby, J.L., Young, R., Jones, C.M. (2019). Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.

    Morb. Mortal Wkly Rep. 2019; 68:679-686, doi: http://dx.doi.org/10.15585/mmwr.mm6831e1

  10. 10

    Issue Brief: Health Disparities Related to Opioid Misuse in Appalachia. (2019).

    In Creating a Culture of Health in Appalachia: Disparities and Bright Spots. East Tennessee State University and NORC at the University of Chicago. https://healthinappalachia.org/issue-briefs/opioid-misuse/

  11. 11

    Jackson, J.R. (2019). Examining the Variability In and Impact of State-Level Regulations of Opioid Treatment Programs.

    Dissertation, Richard M. Fairbanks, School of Public Health, Indiana University.

  12. 12

    Johnson S., Cohen Z. & Waqar T. (2019). Centralized pharmacy for validating prescription drugs.

    U.S. Patent Application No. 16/001,737, http://www.freepatentsonline.com/y2019/0378598.html

  13. 13

    Masterman, C.J. (2018). An Empirical Analysis of Policy Responses to the Opioid Epidemic.

    Dissertation, Vanderbilt University.

  14. 14

    Miller, A. (2019). Escaping Death: Naloxone’s Chemical Nature and Potential to Combat the Opioid Epidemic.

    Honors Theses, University of Nebraska-Lincoln, 102.

  15. 15

    Musse I. (2019). Employment Shocks and Demand for Pain Medication.

    Department of Economics, University of Illinois at Urbana-Champaign, https://economics.illinois.edu/sites/default/files/assoc-files/285/painkillers_imusse.pdf

  16. 16

    Newman, K. (2019). Study: Overdose Antidote Has Been in Short Supply at Philadelphia Pharmacies.

    U.S. News & World Report. June 7, 2019. https://www.usnews.com/news/healthiest-communities/articles/2019-06-07/overdose-antidote-has-been-in-short-supply-at-philadelphia-pharmacies

  17. 17

    Stancliff, S., Medley, B., Mathews, W. (2018). Harm Reduction: Caring for People Who Misuse Opioids. In M.T. Compton, & M. Manseau, (Eds.),

    The American Opioid Epidemic: From Patient Care to Public Health (pp. 337-360). Washington, DC: American Psychiatric Association Publishing.

Other Prescription Drug Abuse Policy Datasets
  1. 1

    Sonderegger Research Center, University of Wisconsin-Madison School of Pharmacy. State Laws and Other Regulatory Policies Related to Pain Care Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through December 31, 2017. Available at: http://lawatlas.org/datasets/state-laws-and-other-regulatory-policies-related-to-pain-care-final

  2. 2

    Heins, S.E. Morphine Equivalent Daily Dose (MEDD) Policies Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through June 1, 2017. Available at: http://lawatlas.org/datasets/morphine-equivalent-daily-dose-medd-policies